Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer

August 2001

Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer seem to have a higher risk of osteoporosis.

This makes sense.

These drugs slow the growth of prostate cancer by suppressing testosterone production.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Cholesterol Bayer is taking Baycol (cerivastatin) off the market
new thinking on which women should take hormone replacement therapy
Cardiology ACE inhibitors and diuretics can prevent recurrent stroke
Cardiology measuring C-reactive protein levels...to help identify patients who could benefit from statins
Renal & Urology more attention focused on urinary incontinence
Infectious Diseases Valtrex (valacyclovir) for just 3 days when treating recurrent genital herpes
Comtan (entacapone), a new COMT inhibitor for advanced Parkinson's disease
new treatment algorithm to select drugs for Parkinson's disease
warning about Serzone (nefazodone) possibly causing liver toxicity
Gastroenterology acid blockers for some patients with irritable bowel syndrome
Pediatrics iron deficiency might reduce cognitive ability in school-aged kids
Dermatology topical phenytoin for wound healing
Osteoporosis best way to switch women from estrogen replacement therapy to Evista (raloxifene)
Osteoporosis Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer
Anticoagulants new guidelines on using low-molecular-weight heparins (Lovenox, Fragmin, Fraxiparine, Innohep)
Cannabinoids Canada is now the first country to legalize MEDICAL marijuana